299 related articles for article (PubMed ID: 34012920)
1. Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study.
Zhang G; Gong S; Pang L; Hou L; He W
Front Oncol; 2021; 11():659217. PubMed ID: 34012920
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial.
Liu Q; Xu JY; Xu YH; Chen M; Deng LC; Wu JP; Zhou T; Zhang LQ; Tan J; Pu XX; Shang YL; Hua J; Li YQ; Cai W; Gu YL; Peng XC; Chan PC; Jabbour SK; Nam HS; Hua D
Transl Lung Cancer Res; 2022 May; 11(5):832-844. PubMed ID: 35693282
[TBL] [Abstract][Full Text] [Related]
3. Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma.
Mao J; Yang X; Lin J; Yang X; Wang D; Zhang L; Bai Y; Bian J; Long J; Xie F; Huang H; Sang X; Chen S; Zhao H
J Cancer; 2021; 12(5):1555-1562. PubMed ID: 33532001
[No Abstract] [Full Text] [Related]
4. Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study.
Yanwei L; Feng H; Ren P; Yue J; Zhang W; Tang P; Shang X; Pang Q; Liu D; Chen C; Pan Z; Tao YZ
Oncologist; 2020 Oct; 25(10):e1464-e1472. PubMed ID: 32342599
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
Li J; Qin S; Wen L; Wang J; Deng W; Guo W; Jia T; Jiang D; Zhang G; He Y; Ba Y; Zhong H; Wang L; Lin X; Yang J; Zhao J; Bai Y; Wu X; Gao F; Sun G; Wu Y; Ye F; Wang Q; Xie Z; Yi T; Huang Y; Yu G; Lu L; Yuan Y; Li W; Liu L; Sun Y; Sun Y; Yin L; Hou Z
BMC Med; 2023 May; 21(1):173. PubMed ID: 37147645
[TBL] [Abstract][Full Text] [Related]
7. The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study.
Wang D; Yang X; Long J; Lin J; Mao J; Xie F; Wang Y; Wang Y; Xun Z; Bai Y; Yang X; Guan M; Pan J; Seery S; Sang X; Zhao H
Front Oncol; 2021; 11():646979. PubMed ID: 33912461
[TBL] [Abstract][Full Text] [Related]
8. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
Xie L; Xu J; Sun X; Tang X; Yan T; Yang R; Guo W
Oncologist; 2019 Jul; 24(7):e542-e550. PubMed ID: 30559126
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study.
Geng Q; Shen H; Zhu W; Lu Y; Wang M; Jiang H; Li D
Onco Targets Ther; 2020; 13():11529-11535. PubMed ID: 33204107
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma.
Lin G; Wang B; Wu X; Sun T; Chen L; Lu C; Wang N
Cancer Manag Res; 2020; 12():11523-11526. PubMed ID: 33204163
[TBL] [Abstract][Full Text] [Related]
12. Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial.
Hou Z; Zhu K; Yang X; Chen P; Zhang W; Cui Y; Zhu X; Song T; Li Q; Li H; Zhang T
Ann Transl Med; 2020 Sep; 8(17):1047. PubMed ID: 33145266
[TBL] [Abstract][Full Text] [Related]
13. The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study.
Sun F; Lu S; Zhen Z; Zhu J; Wang J; Huang J; Zhang Y; Li H; Cai R; Liu M; Wu L; Sun X; Zhang Y
Cancer Manag Res; 2020; 12():6177-6185. PubMed ID: 32801866
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial.
Wang J; Huang D; Yang W; Song Q; Jia Y; Chen P; Cheng Y
Front Oncol; 2022; 12():1030798. PubMed ID: 36505785
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC.
Wu D; Liang L; Nie L; Nie J; Dai L; Hu W; Zhang J; Chen X; Han J; Ma X; Tian G; Han S; Long J; Wang Y; Zhang Z; Xin T; Fang J
Asia Pac J Clin Oncol; 2018 Dec; 14(6):446-452. PubMed ID: 29573236
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Adverse Events of Apatinib Salvage Treatment for Refractory Diffuse Malignant Peritoneal Mesothelioma: A Pilot Study.
Yang ZR; Su YD; Ma R; Wu HL; Li Y
Front Oncol; 2022; 12():811800. PubMed ID: 35847956
[TBL] [Abstract][Full Text] [Related]
17. Apatinib mesylate tablet in the treatment of advanced malignant melanoma.
Yang L; Zhu H; Luo P; Chen S; Xu Y; Wang C
Onco Targets Ther; 2018; 11():5333-5338. PubMed ID: 30214239
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of apatinib in patients with recurrent uterine malignancy: a prospective, single-center, single-arm, phase 2 study.
Ren Y; Wang T; Cheng X; Ke G; Huang Y; Yang H; Huang X; Tian W; Wang H
Ann Transl Med; 2023 Jan; 11(2):106. PubMed ID: 36819505
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
